2018
DOI: 10.1016/j.colsurfb.2018.07.030
|View full text |Cite
|
Sign up to set email alerts
|

Functionalization of graphene family nanomaterials for application in cancer therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
53
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
9
1

Relationship

2
8

Authors

Journals

citations
Cited by 69 publications
(54 citation statements)
references
References 121 publications
1
53
0
Order By: Relevance
“…2,4 Additionally, GO can be functionalized with different molecules such as dispersants, imaging agents, targeting and therapeutic molecules, making this material a perfect platform for theragnostic and multimodal applications. 2,4 However, several issues still need to be addressed. Currently, application of GO in the biomedical field is ruled by the dichotomy between efficiency of the treatment (in vivo or in vitro) and the GO toxicity.…”
Section: Introductionmentioning
confidence: 99%
“…2,4 Additionally, GO can be functionalized with different molecules such as dispersants, imaging agents, targeting and therapeutic molecules, making this material a perfect platform for theragnostic and multimodal applications. 2,4 However, several issues still need to be addressed. Currently, application of GO in the biomedical field is ruled by the dichotomy between efficiency of the treatment (in vivo or in vitro) and the GO toxicity.…”
Section: Introductionmentioning
confidence: 99%
“…19 Besides, the addition of rGO in the mixing solution usually causes a poor water solubility and undesired aggregation which can adversely affect cellular behaviour and fate. 20 To address these problems, the aim of the present study is twofold. Firstly, it attempts to improve the fabrication method of the 3D graphene-alginate composite scaffolds that uses a simple, scalable and environmentally sustainable fabrication technique involving solution mixing, freeze-drying, crosslinking, and bio-reduction.…”
Section: Introductionmentioning
confidence: 99%
“…The acid‐labile D‐DOX was designed as drug–drug conjugate for tumor intracellular pH‐triggered release, by conjugating two doxorubicin (DOX) molecules with one ADH molecule through acid‐labile hydrazone linkage between the carbonyl group in DOX and the hydrazide groups in ADH (Scheme ). To endow the blood stability, improve the pharmacokinetic and pharmacodynamic outcomes of therapeutics, and tailor the particles size of the proposed DSDS prodrug nanoparticles by micellization, the D‐DOX dimer was mono‐PEGylated or bi‐PEGylated with methoxy‐poly(ethylene glycol)‐carboxylic acid (mPEG‐COOH) as prodrug surfactant, via the amidation on one or two amino groups in the D‐DOX dimer. The success synthesis of the D‐DOX dimer and the PEGylated D‐DOX prodrug surfactants were revealed by the 1 H NMR analysis ( Figures and ).…”
Section: Resultsmentioning
confidence: 99%